You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究升石藥(01093.HK)目標價至19.8元評級「買入」
阿思達克 07-08 10:18

匯豐環球研究發表報告指,雖然石藥(01093.HK)旗下去年銷售額達17億元人民幣的藥品歐來寧(Oulaining)被列入今年7月1日發布的首份全國重點監控目錄,但由於集團目前重磅藥品的市場滲透率可進一步提高,及今年下半年新藥品銷售提升,因此該行仍然看好集團的全年業績表現。

該行上調對石藥的股份目標價,由19.2元升至19.8元,評級維持「買入」,但今年至2021年的銷售預測分別下調6%、4.8%及2.3%,以反映在全國重點監控目錄下歐來寧的銷售可能出現下滑。而今明兩年的純利預測亦分別下調3.9%及1.5%。

不過,該行預計,集團在今年至2021年的純利年均複合增長率仍將達24%,並相信投資者過度擔心恩必普(NBP)的專利到期,以及新產品延遲至2022年後。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account